Title: An introduction to Dynamic Contrast-Enhanced MRI Speaker: Dr. Steven Sourbron, PhD Email: <u>s.sourbron@leeds.ac.uk</u> Web: <u>http://medhealth.leeds.ac.uk/profile/500/407/steven\_sourbron</u> Course: weekend educational on perfusion Duration: 40min Contents:

- What is DCE-MRI? A historical perspective
- Which parameters can be measured with DCE-MRI?
- When should DCE-MRI be used?
- Acquisition and analysis steps in DCE-MRI
- Sources of error in DCE-MRI

### What is DCE-MRI? A historical perspective

Indicator-dilution experiments are a class of physiological measurements where an indicator is injected in the body, and the properties of body fluids are determined by analysing the indicator's concentration as a function of time in a region of interest [Zierler1961, Perl1975, Lassen1979, Jacquez1985]. These methods were first translated into MRI in the mid 1980's, using (currently standard) MRI contrast agents as indicators for the extracellular fluid [Runge1984, Pettigrew1986]. These early studies used T1-weighted sequences to assess the indicator concentration as a function of time after injection. This method is now generally referred to as Dynamic Contrast-Enhanced MRI or DCE-MRI. It was later discovered that the signal changes in normal brain tissue (ie. in the absence of contrast agent leakage) were much stronger when T2\*-weighted sequences were used [Villringer1998]. This method is now known as Dynamic Susceptibility Contrast MRI or DSC-MRI [Choyke1989, Rosen1990].

#### Which parameters can be measured with DCE-MRI?

The target parameters (biomarkers) of any DCE-MRI experiment can be separated into two main groups [Sourbon2012]. The "perfusion" parameters characterize the microvasculature: tissue blood flow (in ml blood per min and per ml tissue), tissue blood volume (in ml blood per ml tissue) and blood mean transit time (in sec). The "permeability" parameters characterize the leakage of indicator into the extravascular space: the permeability-surface area product PS (in 1/min), the interstitial volume (in ml per ml tissue) and the interstitial mean transit time (in min). An especially important physiological parameter is the volume transfer constant (Ktrans), which measures the rate at which indicator is delivered to the extravascular space (in 1/min). Ktrans is not an independent parameter but a combination of perfusion and permeability parameters. However, as the delivery of nutrients is ultimately the main function of the microvascular bed, Ktrans is a more direct measure of tissue function. Some other parameters can be measured which are specific to certain organs, such as the glomerular filtration rate (in the kidney) or the portal-venous fraction of tissue perfusion (in the liver).

#### When should DCE-MRI be used?

The discovery of Villringer et al [Villringer1988] led in the 1990's to a paradigm where DSC-MRI was considered the method of choice for the measurement of perfusion parameters [Rosen1990, Kuhl1997], and DCE-MRI the method of choice for the measurement of permeability parameters [Tofts1989, Larsson1990, Brix1991]. At the turn of the century it became increasingly clear that absolute quantification with DSC-MRI is more difficult, and the weaker signal enhancement of DCE-MRI in the first pass is only a limitation in the brain. Today, DCE-MRI remains the method of choice

for the measurement of permeability [Tofts1997, Leach 2005], and has replaced DSC-MRI as the method of choice for the measurement of perfusion in all areas except the brain: eg. in the liver [Materne2002, Pandharipande2005], tumours [Brix2004, Kershaw2009], myocardium [Jerosch-Herold 2004], kidney [Vallee2000, Dujardin2005], lungs [Risse2006] or skeletal muscle [Lutz2004].

# Acquisition and analysis in DCE-MRI

DCE-MRI is usually performed with a standard dose (0.1 mmol/kg) of a clinical contrast agent (Gd-DTPA) injected at a flow rate of 2-3ml/s [Sourbron2010]. The acquisition is either performed with a 2D spolied gradient-echo sequence with a non-selective preparation pulse, or a 3D spoiled gradientecho sequence in the steady-state. A critical parameter in the optimisation of a sequence is the temporal resolution. For most accurate quantification, this must be significantly shorter than the typical width of the first-pass in the blood, and also shorter than the mean transit time of blood. As this is in the range of seconds, this requires significant compromises in terms of spatial resolution and/or coverage. Hence for clinical applications where absolute accuracy is less important and/or spatial resolution is more critical, the optimum acquisition may represent a compromise [Ledsam2013]. Alternatively, a separate measurement may be performed to determine the blood concentrations [Risse2006]. It is also common to include T1-mapping before contrast injection to calibrate the dynamic sequence [Kershaw2009].

As in DSC-MRI, the analysis of the data requires the extraction of a reference concentration in arterial blood (the arterial input function or AIF), a signal analysis step to convert measured signals into concentrations, and a tracer-kinetic analysis step to relate the concentrations to the targeted perfusion or permeability parameters. In abdominal organs it may also be necessary to include an image registration step to minimise or remove the breathing or cardiac motion.

# Sources of error in DCE-MRI

The accuracy and precision of DCE-MRI is critically dependent on the details of the acquisition and analysis setup. The most significant errors are often caused by inaccurate measurement of the concentration in the AIF [Sourbron2010]. A particular problem is the rapidly flowing blood, which may cause a flow-weighting that corrupts the concentration estimates if not properly mimized by sequence optimisation or accounted for in the signal analysis. In areas like the brain, where the feeding arteries are relatively small, the AIF concentrations may be corrupted by partial volume effects. Also, since the concentrations in the blood are very high, their estimates may be corrupted by signal saturation and/or T2-interference.

Other errors that may arise on the level of signal analysis are discrepancies between actual and nominal flip angle due to B1-effects or slice profiles, errors in the signal model due to imperfect spoiling, or a bi-exponential T1-recovery due to limited water exchange between tissue compartments with different concentrations.

A more fundamental problem arises if (some of) the targeted parameters are essentially unmeasurable. For instance, if the exchange of contrast agent between intra- and extravascular spaces is very fast (high PS), then blood and interstitium are at equal concentrations at all times and their volume fractions are not separately measurable. Any attempt to measure the blood volume under such conditions will produce unreliable results. The problem is that this may not always be obvious a priori since PS is an unknown, and the problem may only exist in part of the organ. For clinical practice it is therefore important to supply an error estimate with any measured parameter, so that unreliable values are not overinterpreted.

### References

[Zierler1961] Zierler KL. Theory of the use of arteriovenous concentration differences for measuring metabolism in steady and non-steady states. J. Clin. Invest. 1961; 40(12): 2111–2125.

[Perl1975] Perl W, Lassen NA, Effros RM. Matrix proof of flow, volume and mean transit time theorems for regional and compartmental systems. Bull. Math. Biol. 1975; 37(6): 573–588.

[Lassen1979] Lassen N, Perl W. Tracer Kinetic Methods in Medical Physiology. Raven Press: New York, 1979.

[Jacquez1985] Jacquez J. Compartmental Analysis in Biology and Medicine, 2nd edn. University of Michigan Press: Michigan, 1985.

[Runge1984] Runge VM, Clanton JA, Herzer WA, Gibbs SJ, Price AC, Partain CL, James AE. Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 1984; 153(1): 171–176.

[Pettigrew1986] Pettigrew RI, Avruch L, Dannels W, Coumans J, Bernardino ME. Fastfield-echo MR imaging with Gd-DTPA: physiologic evaluation of the kidney and liver. Radiology 1986; 160(2): 561–563.

[Villringer1988] Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, Brady TJ. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn. Reson. Med. 1988; 6(2): 164–174.

[Choyke1989] Choyke PL, Frank JA, Girton ME, Inscoe SW, Carvlin MJ, Black JL, Austin HA, Dwyer AJ. Dynamic Gd-DTPA-enhanced MR imaging of the kidney: experimental results. Radiology 1989; 170(3): 713–720.

[Rosen1990] Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn. Reson. Med. 1990; 14(2): 249–265.

[Sourbron2012] Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys. Med. Biol. 2012; 57(2): R1–33.

[Kuhl1997] Kuhl CK, Bieling H, Gieseke J, Ebel T, Mielcarek P, Far F, Folkers P, Elevelt A, Schild HH. Breast neoplasms: T2\* susceptibility-contrast, first-pass perfusion MR imaging. Radiology 1997; 202(1): 87–95.

[Tofts1989] Tofts PS, Kermode AG. Blood brain barrier permeability in multiple sclerosis using labelled DTPA with PET, CT and MRI. J. Neurol. Neurosurg. Psychiatry 1989; 52(8): 1019–1020.

[Larsson1990] Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O,Paulson OB. Quantitation of blood–brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn. Reson. Med. 1990; 16(1): 117–131.

[Brix1991] Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS GD-DTPA enhanced MR imaging. J.Comput. Assist. Tomogr. 1991; 15(4): 621–628.

[Tofts1997] Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging 1997; 7(1): 91–101.

[Leach2005] Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 2005; 92(9): 1599–1610.

[Materne2002] Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, Beers BEV. Assessment of hepatic perfusion parameters with dynamic MRI. Magn. Reson. Med. 2002; 47(1): 135–142.

[Pandharipande2005] Pandharipande P, Krinsky G, Rusinek H, Lee V. Perfusion imaging of the liver: current challenges and future goals. Radiology 2005; 234(3): 661–673.

[Brix2004] Brix G, Kiessling F, Lucht R, Darai S, Wasser K, Delorme S, Griebel J. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn. Reson. Med. 2004; 52(2): 420–429.

[Kershaw2009] Kershaw L, Hutchinson C, Buckley D. Benign prostatic hyperplasia:evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI. J. Magn. Reson. Imaging 2009; 29(3): 641–648.

[Jerosch-Herold2004] Jerosch-Herold M, Seethamraju R, Swingen C, Wilke N, Stillman A. Analysis of myocardial perfusion MRI. J. Magn. Reson. Imaging 2004; 19(6): 758–770.

[Vallee2000] J-P. Vallee, F. Lazeyras, HG Khan, F. Terrier. Absolute renal blood flow quantification by dynamic MRI and Gd-DTPA. Eur Radiol 2000; 10: 1245-52.

[Dujardin2005] Dujardin M, Sourbron S, Luypaert R, Verbeelen D, Stadnik T. Quantification of renal perfusion and function on a voxel-by-voxel basis: a feasibility study. Magn. Reson. Med. 2005; 54(4): 841–849.

[Risse2006] F. Risse, W. Semmler, H-U Kauczor, C. Fink. Dual-bolus approach to quantitative measurement of pulmonary perfusion by contrast-enhanced MRI. J Magn Reson Imaging 24: 1284-90.

[Lutz2004] AM. Lutz, D. Weishaupt, BR. Amann-Vesti, T. Pfammatter, K. Goepfert, B. Marincek, D. Nanz. Assessment of skeletal muscle perfusion by contrast medium first-pass magnetic resonance imaging: Technical feasibility and preliminary experience in healthy volunteers. J Magn Reson Imaging 2004;20: 111-121.

[Sourbron2010] S. Sourbron. Technical aspects of MR perfusion. Eur J Radiol; 76: 304-13.

[Ledsam2013] J. Ledsam, R Hodgson, R Moots and S Sourbron. Modelling DCE-MRI at low temporal resolution: a case study in rheumatoid arthritis. J Magn Reson Imaging 38: 1554-63.